Oppenheimer Asset Management Inc. acquired a new position in Celgene Corporation (NASDAQ:CELG) during the first quarter, Holdings Channel reports. The institutional investor acquired 122,841 shares of the biopharmaceutical company’s stock, valued at approximately $15,286,000.

Several other institutional investors also recently modified their holdings of CELG. Swiss National Bank increased its position in shares of Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after buying an additional 588,000 shares during the period. Edge Wealth Management LLC increased its position in shares of Celgene Corporation by 10.5% in the first quarter. Edge Wealth Management LLC now owns 15,920 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,518 shares during the period. Boston Partners increased its position in shares of Celgene Corporation by 0.3% in the first quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock worth $24,620,000 after buying an additional 541 shares during the period. Catawba Capital Management VA increased its position in shares of Celgene Corporation by 12.0% in the first quarter. Catawba Capital Management VA now owns 2,425 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 260 shares during the period. Finally, Chicago Equity Partners LLC increased its position in shares of Celgene Corporation by 148.8% in the first quarter. Chicago Equity Partners LLC now owns 86,480 shares of the biopharmaceutical company’s stock worth $10,761,000 after buying an additional 51,715 shares during the period. Institutional investors own 78.41% of the company’s stock.

Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.40% during mid-day trading on Friday, reaching $130.89. The company’s stock had a trading volume of 924,875 shares. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The firm has a market cap of $102.40 billion, a PE ratio of 40.54 and a beta of 1.89. The firm’s 50 day moving average is $134.23 and its 200 day moving average is $124.17.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.44 earnings per share. On average, equities analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/oppenheimer-asset-management-inc-acquires-shares-of-122841-celgene-corporation-nasdaqcelg.html.

CELG has been the subject of a number of research analyst reports. BTIG Research reiterated a “buy” rating and issued a $138.00 target price on shares of Celgene Corporation in a report on Wednesday, May 24th. Argus upgraded Celgene Corporation from a “hold” rating to a “buy” rating and lifted their target price for the stock from $96.93 to $160.00 in a report on Monday, July 31st. Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 target price on shares of Celgene Corporation in a report on Tuesday, July 11th. Zacks Investment Research downgraded Celgene Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, Cantor Fitzgerald set a $160.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $147.00.

In other news, insider Robert J. Hugin sold 175,970 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now directly owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the transaction, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 235,255 shares of company stock worth $31,377,042. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.